- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03903770
Personalized Upper Extremity Rehabilitation for Persons With Stroke (SUPER)
February 18, 2020 updated by: Philippe Archambault, McGill University
Personalized Upper Extremity Rehabilitation for Persons With Moderate and Severe Impairments Due to Stroke
Approximately 80% of individuals with chronic stroke present with long lasting upper extremity (UE) impairments.
Advances in rehabilitation technology, such as robotics, virtual reality (VR) and neuromuscular electrical stimulation (NMES), have separately demonstrated their effectiveness in improving UE function of individuals with stroke.
The potential to influence recovery may be further enhanced by combining these modalities in order to target motor deficits of the individual.
Research has shown that not all persons with stroke may be able to recover hand function.
In particular, such recovery depends on the integrity of the corticospinal tract (CST), which links the motor areas of the brain to the UE (and hand) musculature.
Instead of using a 'one-size-fits-all' approach to UE rehabilitation, CST integrity will be assessed through transcranial magnetic stimulation (TMS), a non-invasive approach, and match the intervention to the individual's specific impairments.
The perSonalized UPper Extremity Rehabilitation (SUPER) intervention is proposed, which combines robotics, VR activities, and NMES.
The objectives of this study are to determine the feasibility of the SUPER intervention in individuals with moderate/severe stroke.
Stroke participants will receive a 5-week intervention (3x per week) combining robotic therapy and VR activities, based on their functional level.
Those with low potential for hand recovery will receive an intervention focussing on elbow and shoulder movements.
For those with a good potential for hand recovery, the last 30 minutes of the robotic or VR session will be complemented by muscle-triggered NMES.
Feasibility indicators associated with process, resources, management and treatment will be measured.
Outcomes of UE and hand function will include the Fugl-Meyer upper extremity assessment, the Box and Block test and the ABILHAND.
It is expected that feasibility criteria will be met and that the SUPER intervention will lead to significant improvements in UE impairment compared to a waitlist group.
Study Overview
Study Type
Interventional
Enrollment (Actual)
32
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Quebec
-
Laval, Quebec, Canada, H7V1R2
- Jewish Rehabilitation Hospital
-
Sherbrooke, Quebec, Canada, J1H 4C4
- Centre de Recherche sur le Vieillissement
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 85 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- ischemic or hemorrhagic stroke
- moderate to severe UE impairment (score between 2 and 4 out of 7 on the Chedoke-McMaster each of the arm and hand components
- at least 3 months post stroke
- no longer receiving rehabilitation services.
Exclusion Criteria:
- medical instability
- marked cognitive deficits (MiniCog score 2 or lower)
- uncorrected visual impairments
- shoulder pain that would limit participation in the study
- severe spasticity at the affected UE
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Intervention
Upper extremity rehabilitation
|
Participants receive the SUPER intervention 3 times per week for 1 hr, during 4 weeks.
For participants with a low recovery potential for hand function, the SUPER interventions consists in robot-assisted reaching movements and unilateral and bilateral VR activities.
The robot-assisted activity consists of a reaching task to six targets placed at maximal reach distance.
For the VR activity, we use a reach and grasp VR activity based on a shopping task.
Participants with good potential for hand recovery also receive 30 min of electromyography-triggered muscle stimulation, combined with the VR activity.
The muscle stimulation is triggered when the participant attempts to grasp a virtual object and helps with hand opening movements.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change from baseline Fugl-Meyer Assessment (Upper extremity section) at 6 weeks
Time Frame: 6 weeks
|
A performance-based measure of UE impairment describing motor recovery
|
6 weeks
|
|
Change from baseline Box and Blocks Test at 6 weeks
Time Frame: 6 weeks
|
A measure of gross motor dexterity
|
6 weeks
|
|
Change from baseline ABILHAND at 6 weeks
Time Frame: 6 weeks
|
A questionnaire to assess active function of the upper limbs with 23 activities, rated as impossible, difficult or easy.
The scale is scored through Rasch analysis, providing a total score ranging from -6 to +6, with higher scores indicating a lower degree of upper extremity impairment.
|
6 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change from baseline Motor Activity Log at 6 weeks
Time Frame: 6 weeks
|
A questionnaire rating the quality and frequency of use of the upper extremity in 14 everyday tasks.
Each task is rated on two scales: quantity, assessing how much the affected extremity is used in the task; and quality, assessing how well does the affected extremity perform in the task.
A 0 to 5 scale is used for quantity and quality (0 = not at all; 5 = same as before stroke).
Answers are averaged for each sub scale and a percentage is calculated.
A higher score indicates lower level of impairment.
|
6 weeks
|
|
Change from baseline Grip Strength at 6 weeks
Time Frame: 6 weeks
|
Maximal hand grip strength measured with a dynamometer
|
6 weeks
|
|
Change from baseline Stroke Impact Scale at 6 weeks
Time Frame: 6 weeks
|
A stroke-specific health status measure featuring 16 items capturing daily activities.
This scale has 8 sub-scales, evaluating: strength, hand function, mobility, activities of daily living, emotion, memory, communication and social participation.
Each is rated on a 0 to 100 range (100 corresponding to least impact of stroke).
An overall score is also calculated (average of sub-scales).
|
6 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
September 1, 2018
Primary Completion (Actual)
December 1, 2019
Study Completion (Actual)
December 1, 2019
Study Registration Dates
First Submitted
February 28, 2019
First Submitted That Met QC Criteria
April 3, 2019
First Posted (Actual)
April 4, 2019
Study Record Updates
Last Update Posted (Actual)
February 19, 2020
Last Update Submitted That Met QC Criteria
February 18, 2020
Last Verified
February 1, 2020
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CRIR-1271-1017
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.